Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs

Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24–88%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no candidate has yet reached regulatory approval. Here, we...

Full description

Bibliographic Details
Main Authors: Courtney L. Finch, Thomas H. King, Kendra J. Alfson, Katie A. Albanese, Julianne N. P. Smith, Paul Smock, Jocelyn Jakubik, Yenny Goez-Gazi, Michal Gazi, John W. Dutton, Elizabeth A. Clemmons, Marc E. Mattix, Ricardo Carrion, Thomas Rudge, Alex Ridenour, Sovann F. Woodin, Ruth Hunegnaw, Nancy J. Sullivan, Rong Xu
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Vaccines
Subjects:
Marburg virus
adenovirus
vaccine
glycoprotein
filovirus
nonhuman primate
Online Access:https://www.mdpi.com/2076-393X/10/11/1935

Internet

https://www.mdpi.com/2076-393X/10/11/1935

Similar Items